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Abstract
Background: The purpose of this study is to investigate the potential to reduce exposure of the contralateral
hippocampus in radiotherapy for glioblastoma using volumetric modulated arc therapy (VMAT).
Methods: Datasets of 27 patients who had received 3D conformal radiotherapy (3D-CRT) for glioblastoma with a
prescribed dose of 60Gy in fractions of 2Gy were included in this planning study. VMAT plans were optimized with
the aim to reduce the dose to the contralateral hippocampus as much as possible without compromising other
parameters. Hippocampal dose and treatment parameters were compared to the 3D-CRT plans using the Wilcoxon
signed-rank test. The influence of tumour location and PTV size on the hippocampal dose was investigated with
the Mann–Whitney-U-test and Spearman’s rank correlation coefficient.
Results: The median reduction of the contralateral hippocampus generalized equivalent uniform dose (gEUD) with
VMAT was 36 % compared to the original 3D-CRT plans (p < 0.05). Other dose parameters were maintained or
improved. The median V30Gy brain could be reduced by 17.9 % (p < 0.05). For VMAT, a parietal and a non-temporal
tumour localisation as well as a larger PTV size were predictors for a higher hippocampal dose (p < 0.05).
Conclusions: Using VMAT, a substantial reduction of the radiotherapy dose to the contralateral hippocampus for
patients with glioblastoma is feasible without compromising other treatment parameters. For larger PTV sizes, less
sparing can be achieved. Whether this approach is able to preserve the neurocognitive status without compromising
the oncological outcome needs to be investigated in the setting of prospective clinical trials.
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Background
Glioblastoma multiforme (GBM) constitutes one of the
most frequent and most lethal primary brain tumours,
with an annual incidence rate of approximately 3 in
100,000 people in the US and only about 36 % of pa-
tients surviving the first year after initial diagnosis [1].
The standard treatment approach for GBM is trimodal,
with maximal safe resection, if feasible, followed by ra-
diochemotherapy and temozolomide-based maintenance
chemotherapy. However, radiotherapy of the brain may
have side-effects, which include radiation necrosis, cog-
nitive impairment, and others [2–5]. The dose to the
hippocampus is associated with radiation induced mem-
ory impairment [6–9]. Since modern radiotherapy tech-
niques such as intensity-modulated radiotherapy (IMRT)
and volumetric modulated arc therapy (VMAT) allow
for the delivery of highly conformal dose distributions,
the idea arose to selectively spare the hippocampus dur-
ing brain radiotherapy [10]. In this planning study, the
potential to spare the contralateral hippocampus in
radiotherapy for glioblastoma using the VMAT tech-
nique is investigated for 27 patients. Resulting dose vol-
ume histogram (DVH) statistics are compared to clinical
standard 3D-conformal radiotherapy (3D-CRT) plans.
Methods
Datasets of 27 patients who had received 3D-CRT for
glioblastoma at the department of radiation oncology at
the Ludwig-Maximilians University of Munich (LMU)
between 2010 and 2012 were included in this planning
study. For all patients, the prescription to the planning
target volume (PTV) was 60Gy in 30 fractions. The pa-
tient characteristics are shown in Table 1. Patients were
positioned in supine position and immobilized with a
thermoplastic mask. Normal structures like the eyes, the
lenses, the optic nerves, the chiasm, the brain stem were
contoured and designated as organs-at-risk (OARs). Ex-
panded contours were created with safety margins of
3 mm around the brain stem and the chiasm and 5 mm
around the optic nerve. The hippocampus was con-
toured on the T1 MRI sequence as described by Chera
et al. [11]. The VMAT plans were optimised in the re-
search treatment planning system (TPS) Hyperion V2.44
(equivalent to Elekta Monaco 5.1) which relies on the
XVMC algorithm (X-ray voxel Monte Carlo [12]) for
dose calculation. All VMAT plans were generated for a
6MV Elekta Axesse linear accelerator (LINAC) equipped
with an Agility multileaf-collimator (Elekta, Stockholm,
Sweden). The original clinical 3D-CRT plans were
generated in the TPS Oncentra Masterplan (Elekta,
Stockholm, Sweden) using a pencil beam dose algorithm.
3D-CRT plans were created for Siemens LINACs (Oncor
(19 patients), Primus (4) and Mevatron M (4)) equipped
with an 80 or 58 leaves MLC. Since the aim of this study
was a comparison of clinical planning strategies rather
than a technical comparison between VMAT and 3D-
CRT, the use of two different TPS and dose calculation al-
gorithms is not considered to bias the results significantly.
In both systems, planning was performed independently.
We supposed that slight differences between the beam
models only have small influence on the optimal plan a
dosimetrist can create using these models. The dose grid
was 3×3×3mm3 for both VMATand 3D-CRT plans.
VMAT planning strategy
The VMAT plans were realized with two full 360° copla-
nar arcs in clockwise and counter clockwise directions
and one non-coplanar arc with a length of 180° at couch
angle 55° or −55°, depending on the location: The couch
angle was chosen to minimize the amount of healthy tis-
sue traversed by the beams. The collimator angle for the
coplanar arcs was chosen individually according to the
angle of the hippocampus in the sagittal plane, which
was typically in the range of 50° to 70°. For 11 patients,
this approach did not result in clinically acceptable dose
distributions, and an additional non-coplanar arc was
Table 1 Patient characteristics
Number of patients 27
Male 17 (63.0 %)





Left 15 (55.6 %)
Right 8 (29.6 %)
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introduced at an individually chosen angle. The arc
setup is illustrated in Fig. 1.
Optimisation constraints
The optimisation constraints for OARs are summarized
in Table 2. The dose to the cochlea was limited to 54Gy
when it was not inside or in the direct vicinity of the
PTV (11 patients). For the remaining 16 patients, the
dose was limited to 60Gy to avoid the appearance of hot
spots in the cochlea. The constraint limiting the mean
dose to the contralateral hippocampus was adjusted in-
dividually for each patient. It was attempted to reduce
the dose as much as possible without compromising on
the target coverage and the dose limits for other OARs.
No attempt was made to spare the ipsilateral hippocam-
pus. For patients with bilateral disease (4 cases), the side
bearing a lower tumour volume was the side where the
hippocampal dose was reduced. All plans were reviewed
by a consultant radiation oncologist and approved as
clinically acceptable.
Treatment plan evaluation
To assess the plan quality, the following metrics were
calculated both for the original 3D-CRT and the new
VMAT plans. The percentage of a structure receiving at
least the dose x is calculated with the formula
Vx ¼ VT ;x
VT
where VT,x is the volume of the structure receiving at
least the dose x and VT is the volume of the structure,
both in absolute volume units. The index was used to
evaluate the coverage of the PTV with the prescribed
dose as well as for the evaluation of the exposure of the
brain and the hippocampus. The homogeneity index HI




where Dx% is the dose received by x% of the target vol-
ume. For perfect homogeneity D2 % and D98 % are equal
and HI takes the value 0.0. For inhomogeneous dose dis-
tributions, it takes values >0.0. The conformity index
with respect to the isodose x, CIx, was calculated as pro-
posed by Paddick [14]:
CIx ¼ VT ; xVT 
VT ;x
V x
Where VT and VT,x are calculated for the target volume
and Vx denotes the volume receiving the dose x, including
also volumes outside the target volume (in absolute vol-
ume units). For perfect conformity, CIx takes the value 1.0.
Less conformal dose distributions result in values <1.0. In
this study, CIx was evaluated with respect to the isodoses
100 % and the 95 % of the prescribed dose. To quantify the
dose to the hippocampus, the generalized equivalent uni-
form dose (gEUD) was used. This concept was introduced
by Niemierko [15]. In this approach, two heterogeneous
dose distributions are assumed to be equivalent when they










where the empirical parameter k corresponds to the
strength of the volume effect (for k→∞ the gEUD is the
maximum dose, for k = 1 it corresponds to the mean
Fig. 1 Coronal view of the arc setup. a Two full coplanar arcs (horizontal line) and one arc from gantry angle 0 to 180° at couch angle 55° were
sufficient in most cases (16 patients). b For the remaining 11 patients, an additional non-coplanar arc was introduced
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dose). For the hippocampus, k = 12 was used as previ-
ously described [16].
Doses are reported in absolute planning dose, if not
stated otherwise. For the hippocampus also EQD2
(equivalent dose in 2Gy fractions) values have been calcu-
lated, since these values are often used in the literature.
Statistical analysis
For the statistical comparison of the 3D-CRT and the
VMAT plans implementations of statistical tests in the
software Mathematica, Version 9.0 (Wolfram Research,
Inc., Champaign, IL) were used. When paired samples
were to be compared, as for the comparison of treat-
ment parameters such as target indices and the dose to
the contralateral hippocampus between 3D-CRT and
VMAT the Wilcoxon signed-rank test was used, since a
Kolmogorov-Smirnov test revealed that parametric con-
ditions were not fulfilled in all cases. When different
samples were compared, which was the case when the
influence of the tumour localisation on the hippocampal
dose was investigated, the Mann–Whitney U test was
used. To assess the correlation between the PTV size
and the hippocampal dose, Spearman’s rank correlation
coefficient ρ and corresponding p-values were calcu-
lated. A p-value of 0.05 was considered significant.
Results
In Fig. 2, a comparison of the isodose lines in the same
transversal slice between the VMAT and the 3D-CRT
plans is shown for one exemplary patient case. The re-
duction of the hippocampal dose exposure can be seen
in the 30 % (=18Gy) isodose line.
Target indices
In Table 3 the target indices for the 3D-CRT and the
VMAT plans are shown. The VMAT plans provided a
better homogeneity index and a better conformity index
with respect to the 95 % isodose. The median HI with
VMAT was 0.15, while for 3D-CRT it was 0.18. The me-
dian CI95 % was 0.80 for VMAT compared to 0.70 for
3D-CRT. Both differences were statistically significant
(p < 0.01). No significant differences between the two
techniques were observed according to target coverage
and conformity index with respect to the 100 % isodose.
Dose to the brain
The difference between the mean brain dose for the two
techniques was small but significant (median 34.0Gy for
VMAT vs. 35.7Gy for 3D-CRT, p < 0.01). Additionally,
the percentage of the brain volume receiving 12, 30 and
45Gy was significantly lower for the VMAT technique
(p < 0.01), the largest differences were observed for the
V30Gy (brain) (median 48.2 % for VMAT vs. 58.7 % for
3D-CRT). Details are shown in Table 3.
Dose to the contralateral hippocampus
The dose to the contralateral hippocampus is shown in
Table 3 PTV indices, dose to the brain and to the
Fig. 2 Comparison of VMAT (a) and 3D-CRT (b) dose distributions for one patient. OARs are shown with their avoidance margins. Dose constraints
for optic nerve (violet), chiasm (light brown, only the 3 mm expansion is visible in this slice) and the brain stem (green) prevent the 95 % isodose
from completely covering the PTV (red). The reduced dose to the contralateral hippocampus (yellow) can be seen in the 30 % isodose line. The
5Gy isodose line shows that the dose to the lenses was limited to 5Gy
Table 2 Optimisation constraints
OAR Dose constraint
Lenses Maximum dose≤ 5Gy
Eyes Mean dose≤ 30Gy
Optic nerves Maximum dose≤ 54Gy (5 mm expansion: ≤ 56Gy)
Chiasm Maximum dose≤ 54Gy (3 mm expansion: ≤ 56Gy)
Brainstem Maximum dose≤ 54Gy (3 mm expansion: ≤ 56Gy)
Cochlea Maximum dose≤ 54Gy/60Gy
Hippocampus Chosen individually for each patient
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contralateral hippocampus. All the calculated parameters
(mean dose, maximum dose, gEUD and the percentage
of the contralateral hippocampus volume receiving 10,
15, 20, 30 and 40Gy) were significantly improved in the
VMAT plans (p < 0.01). In particular, the median V20Gy
(hippocampus) improved from 100 % for 3D-CRT to
12.6 % for VMAT and the median V15Gy (hippocampus)
from 100 to 32.2 %. The median gEUD was reduced by
36 % with VMAT.
Correlation between the size of the PTV and the dose to
the hippocampus
Spearman correlation coefficients and p-values are
shown in Table 4. No significant correlation between the
size of the PTV and the hippocampal dose was observed
for 3D-CRT. For the VMAT plans, a significant correlation
(p = 0.01) was found for the hippocampal mean dose,
gEUD and V15Gy (ρ = 0.44,0.47 and 0.41, respectively).
Influence of the PTV localisation on the hippocampal dose
In Table 5, the results of the analysis of the influence of
the tumour localisation on the hippocampal gEUD are
shown. For 3D-CRT, no significant influence of the
tumour localisation on the hippocampal dose was
observed. For VMAT, a parietal localisation appears to
go along with a higher hippocampal dose. The median
gEUD to the hippocampus of all VMAT plans for pa-
tients with parietal involvement was 37.9 Gy, compared
to 21.1Gy for the remaining patients without parietal in-
volvement (p < 0.01). For the subgroup of patients with
no temporal involvement, the dose to the contralateral
hippocampus (median gEUD 31.2 Gy) was higher (p =
0.04) than for the patients with temporal involvement
(median gEUD 19.5Gy).
Table 3 PTV indices, dose to the brain and to the contralateral hippocampus
3D-CRT/median (range) VMAT/median (range) p-value
PTV indices
V95 % 0.88 (0.79–0.97) 0.91 (0.79–0.99) NS (p = 0.05)
V100 % 0.53 (0.17–0.75) 0.56 (0.38–0.84) NS (p = 0.18)
HI 0.18 (0.09–0.24) 0.15 (0.06–0.21) p < 0.01
CI95 % 0.70 (0.32–0.78) 0.80 (0.75–0.91) p < 0.01
CI100 % 0.48 (0.15–0.70) 0.55 (0.36–0.78) NS (p = 0.09)
Brain
Mean dose (Gy) 35.7 (23.7–45.0) 34.0 (24.2–40.3) p < 0.01
V12Gy (%) 89.6 (53.5–98.5) 89.2 (70.7–97.3) p < 0.01
V30Gy (%) 58.7 (31.3–81.0) 48.2 (27.2–62.4) p < 0.01
V45Gy (%) 40.0 (19.0–56.3) 32.9 (17.7–47.7) p < 0.01
Contralateral hippocampus
Mean dose (Gy) 33.1 (12.1–50.1) 14.7 (8.1–40.3) p < 0.01
Mean EQD2 (Gy) 25.7 (7.3–46.0) 9.2 (4.6–33.7) p < 0.01
Max dose (Gy) 39.6 (30.1–59.9) 26.7 (12.6–62.3) p < 0.01
Max EQD2 (Gy) 32.9 (22.6–59.9) 19.3 (7.6–63.5) p < 0.01
gEUD (Gy) 36.3 (24.3–56.1) 23.1 (10.8–56.0) p < 0.01
V10Gy/5.8Gy(EQD2) (%) 100. (44.3–100.) 100. (14.2–100.) p < 0.01
V15Gy/9.4Gy(EQD2) (%) 100. (14.4–100.) 32.3 (0.0–100.) p < 0.01
V20Gy/13.3Gy(EQD2) (%) 100. (8.3–100.) 12.6 (0.0–83.0) p < 0.01
V30Gy/22.5Gy(EQD2) (%) 70.5 (2.2–100.) 3.4 (0.0–69.0) p < 0.01
V40Gy/33.3Gy(EQD2) (%) 1.4 (0.0–100.) 0.4 (0.0–61.3) p < 0.01
Table 4 Correlation of the PTV size with the respective dose to
the contralateral hippocampus
Parameter Spearman’s ρ p-value
3D-CRT
Mean Dose 0.21 NS (p = 0.30)
gEUD 0.33 NS (p = 0.10)
V15Gy/9.4Gy(EQD2) 0.11 NS (p = 0.59)
VMAT
Mean dose 0.44 p = 0.02
gEUD 0.47 p = 0.01
V15Gy/9.4Gy(EQD2) 0.41 p = 0.01
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Discussion
The purpose of this planning study is to investigate the
feasibility of sparing the contralateral hippocampus in
radiotherapy for glioblastoma using VMAT. The hippo-
campal dose and the whole brain V30Gy could be signifi-
cantly improved, while maintaining the same dose
constraints for other OARs. The other investigated pa-
rameters (target coverage, homogeneity index and con-
formity index) could be kept stable or even improved
(dose homogeneity and conformity, whole brain dose).
These results are in agreement with the results found in
similar studies by Canyilmaz et al., who compared stand-
ard IMRT to hippocampal sparing IMRT and VMAT
plans for 20 patients [17], and Marsh et al. who com-
pared standard IMRT plans to IMRT plans with sparing
of the contralateral neural stem cell compartment,
hippocampus and limbic circuit for 5 patients [18]. The
planning strategy in these studies differed from the con-
cept used in our planning study. Both studies used a
dose prescription of 46 Gy in 23 fractions followed by a
sequential boost of 14Gy in 7 fractions (RTOG consen-
sus) and concluded that a substantial reduction of the
dose to the contralateral hippocampus is feasible with
the used techniques without compromising other treat-
ment parameters. In contrast to those studies, we also
attempted to identify influencing factors for the hippo-
campal dose exposure. Studies suggest that it is safe to
reduce the applied margins in IMRT for glioblastoma
[19]. A study by Ali et al. evaluated the effect of reduced
PTV margins on hippocampal dose [20]. They compared
the standard margin of 2 cm (gross tumour volume
(GTV) to clinical target volume (CTV)) with a reduced
margin of 8 mm and reported a significant reduction
of the bilateral hippocampal dose when applying the
reduced margin concept. Concordantly, a significant cor-
relation between the size of the PTV and the dose to the
contralateral hippocampus was observed for VMAT in
our planning study. This correlation was not significant
for the original 3D-CRT plans, which might be explained
by the fact that in the standard clinical protocol hippo-
campal sparing was not a treatment goal, even though it
was attempted to create a dose distribution as conformal
as possible, but the hippocampus was not designated as
an OAR for which the dose exposure should be select-
ively reduced. This is also a limitation of this study. It is
not suited to investigate the question to what extent
VMAT is better in sparing the hippocampus compared
to 3D-CRT from a purely technological perspective,
since the planning objectives were not the same. How-
ever, it allows us to draw conclusions about how much
reduction of the dose exposure can be achieved clinic-
ally, when the standard 3D-CRT planning strategy is re-
placed by a VMAT approach and hippocampal sparing is
incorporated as a planning objective. An unexpected re-
sult of our study is that a parietal tumour localisation
correlated with a higher hippocampal dose for VMAT,
while a temporal localisation correlated with a lower
hippocampal dose. A possible explanation may be the
used planning strategy - for some angles of the non-
coplanar arcs, the contralateral hippocampus is in the
field when the target volume is located on the parietal
lobe. Given that the subgroup of patients with parietal
involvement was small (5 patients), which limits the stat-
istical power of the test and that the p-value for the
comparison between patients with and without temporal
involvement was just under the significance threshold
(p = 0.04), these particular results should be interpreted
with caution. While there have been few studies investi-
gating the feasibility of sparing the hippocampus in radio-
therapy for glioblastoma, more research has been carried
out concerning hippocampal sparing during whole-brain
radiotherapy (WBRT) for patients with brain metastases.
Several studies have investigated the feasibility of sparing
both hippocampi during WBRT [21–24]. Clinical data
suggests that the approach is safe and favourable in terms
of neurological outcome [25–27]. For hippocampal spar-
ing WBRT, also the influence of patient positioning on the
hippocampal dose exposure has been investigated, and
there is data suggesting that an inclined head angle might
be beneficial [28]. In our study, it was not investigated
whether an inclined head angle is able to further improve
hippocampal dose in radiotherapy for glioblastoma, as all
patients were positioned in the standard way. In the set-
ting of WBRT for patients with brain metastases, sparing
the hippocampus is not expected to affect the therapeutic
ratio, since brain metastases rarely occur inside or close to
the hippocampus [29, 30]. By contrast, sparing the hippo-
campus in radiotherapy for GBM is more controversial




gEUD (Gy) 34.3 (26.0–48.6) 40.4 (24.3–56.1) NS (p = 0.09)
Parietal Not parietal
gEUD (Gy) 40.6 (24.3–56.1) 36.0 (26.0–48.0) NS (p = 0.40)
Frontal Not frontal
gEUD (Gy) 38.0 (30.8–48.6) 33.7 (24.3–56.1) NS (p = 0.05)
VMAT
Temporal Not temporal
gEUD (Gy) 19.5 (10.8–43.1) 31.2 (17.9–56.0) p = 0.04
Parietal Not parietal
gEUD (Gy) 37.9 (25.7–56.0) 21.1 (10.8–43.1) p < 0.01
Frontal Not frontal
gEUD (Gy) 22.4 (10.8–48.0) 24.1 (10.8–56.0) NS (p = 0.86)
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because of potential involvement of the subventricular
zone (SVZ) in tumour genesis [31]. Higher doses to the ip-
silateral SVZ have been shown to correlate with improved
progression-free survival [32], and no SVZ contact of the
tumour volume has been shown to be a predictor for
long-term survival [33]. For this reason, only the contra-
lateral hippocampus was spared in this planning study. In
the cases with bilateral tumour, no involvement of the
SVZ was presumed due to the small tumour volume on
the spared side. Whether hippocampal sparing is possible
without increasing the risk of relapse is a matter of on-
going debate [34, 35]. Possible benefits for patients with
regard to neurological toxicity of radiotherapy for glio-
blastoma still need to be evaluated in future clinical trials.
A retrospective analysis by Bodensohn et al. concluded
that sparing might make sense for about 50 % of the pa-
tients receiving radiotherapy for glioblastoma [36].
Conclusions
Using VMAT instead of the standard 3D-CRT planning
procedure, a significant reduction of the dose to the
contralateral hippocampus (median reduction: 36 %) is
feasible. Other treatment parameters can be improved as
well or at least be maintained. Whether this approach is
able to improve the outcome of patients with glioblast-
oma needs to be investigated in the setting of prospect-
ive clinical trials. A larger size of the PTV is a predictor
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